BioSpace News Archive

Business

Orexo Interim Report Q3 2022

Orexo’s partner Trinity Health gives patients within their healthcare network access to vorvida® and deprexis®, the digital therapies for alcohol misuse and depression respectively.

November 3, 2022
·
3 min read
BioMidwest

DaVita Clinical Research Showcases Chronic Kidney Disease and Rare Disease Network, Presents New Research Findings at Kidney Week 2022

DaVita Clinical Research will highlight its latest research during the American Society of Nephrology Kidney Week, being held in Orlando from November 2-6, 2022.

November 3, 2022
·
4 min read
Drug Development

Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004

Eccogene announced that the U.S. Food and Drug Administration has approved the investigational new drug application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist ECC5004 for type 2 diabetes mellitus.

November 3, 2022
·
2 min read
Business

Seven pharma CEOs announce new joint action to accelerate net zero healthcare

CEOs from AstraZeneca, GSK, Merck KGaA, Novo Nordisk, Roche, Samsung Biologics and Sanofi announced joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.

November 3, 2022
·
6 min read
Business

Medivir AB - Interim Report January - September 2022

The measures to increase the pace of patient recruitment have yielded results. The Fostrox study is now progressing as expected.

November 3, 2022
·
5 min read
Drug Development

ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease

ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced the allowance of the proact 1 Phase 3 study protocol for its investigational candidate REACT® by the United Kingdom’s MHRA.

November 3, 2022
·
8 min read
Business

SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

SpringWorks Therapeutics, Inc. reported third quarter financial results for the period ended September 30, 2022 and provided an update on recent company developments.

November 3, 2022
·
14 min read
Business

Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results and recent highlights for the third quarter ended September 30, 2022.

November 3, 2022
·
13 min read
Business

Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022

Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced it will report third quarter 2022 financial results on Thursday, November 10, 2022 following the close of the U.S. financial markets.

November 3, 2022
·
1 min read
Business

CytoSorbents Reports Third Quarter 2022 Financial and Operational Results

CytoSorbents Corporation today reported unaudited financial and operating results for the quarter ended September 30, 2022.

November 3, 2022
·
30 min read